GCP
BCRX icon

GSA Capital Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

GSA Capital Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902K Buy
+90,210
New +$816K 0.06% 575
2026
Q1 		– Sell
-108,229
Closed -$844K – 1723
2025
Q4 		$844K Sell
108,229
-82,065
-43% -$593K 0.07% 459
2025
Q3 		$1.44M Buy
190,294
+78,827
+71% +$656K 0.12% 194
2025
Q2 		$999K Sell
111,467
-167,085
-60% -$1.56M 0.07% 450
2025
Q1 		$2.09M Buy
278,552
+114,068
+69% +$920K 0.19% 58
2024
Q4 		$1.24M Sell
164,484
-121,104
-42% -$919K 0.09% 273
2024
Q3 		$2.17M Sell
285,588
-78,250
-22% -$595K 0.16% 101
2024
Q2 		$2.25M Buy
+363,838
New +$2.01M 0.16% 109
2024
Q1 		– Sell
-178,769
Closed -$1.07M – 1609
2023
Q4 		$1.07M Sell
178,769
-12,758
-7% -$73.9K 0.09% 355
2023
Q3 		$1.36M Buy
191,527
+119,995
+168% +$862K 0.12% 260
2023
Q2 		$504K Sell
71,532
-82,186
-53% -$660K 0.05% 723
2023
Q1 		$1.28M Buy
+153,718
New +$1.48M 0.13% 196
2022
Q4 		– Sell
-19,121
Closed -$241K – 1468
2022
Q3 		$241K Buy
+19,121
New +$246K 0.03% 1075
2021
Q4 		– Sell
-41,116
Closed -$591K – 1411
2021
Q3 		$591K Buy
+41,116
New +$648K 0.06% 597
2021
Q2 		– Sell
-80,197
Closed -$816K – 1320
2021
Q1 		$816K Buy
80,197
+69,697
+664% +$719K 0.14% 174
2020
Q4 		$78K Buy
+10,500
New +$54.1K 0.01% 1118
2020
Q3 		– Sell
-39,599
Closed -$189K – 1243
2020
Q2 		$189K Sell
39,599
-99,065
-71% -$396K 0.11% 367
2020
Q1 		$277K Buy
+138,664
New +$382K 0.07% 536
2019
Q2 		– Sell
-40,383
Closed -$329K – 1440
2019
Q1 		$329K Buy
+40,383
New +$346K 0.03% 942
2017
Q4 		– Sell
-13,086
Closed -$69K – 1554
2017
Q3 		$69K Buy
+13,086
New +$67K ﹤0.01% 1541
2015
Q1 		– Sell
-35,350
Closed -$430K – 2094
2014
Q4 		$430K Sell
35,350
-19,324
-35% -$213K 0.03% 1030
2014
Q3 		$535K Buy
+54,674
New +$670K 0.03% 895

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

GSA Capital Partners's BCRX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 90,210 shares worth $902K. The stake represents 0.06% of the portfolio and ranks #575 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in BCRX as recently as Q4 2025.

GSA Capital Partners first reported a position in BCRX in Q3 2014 and has held it in 22 quarters since. The position peaked at $2.25M in Q2 2024. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • GSA Capital Partners held 90,210 shares of BioCryst Pharmaceuticals worth $902K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new GSA Capital Partners position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #575 holding.
  • GSA Capital Partners first reported a position in BioCryst Pharmaceuticals in Q3 2014 and has held it in 22 quarters since.
  • GSA Capital Partners's BioCryst Pharmaceuticals position peaked at $2.25M in Q2 2024.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.